Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing

Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing

Abstract Background Regulatory approval of next generation sequencing (NGS) by the FDA is advancing the use of genomic-based precision medicine for the therapeutic management of cancer as standard care. Recent FDA guidance for the classification of genomic variants based on clinical evidence to aid...

Full description

Bibliographic Details
Main Authors: Grace K. Dy, Mary K. Nesline, Antonios Papanicolau-Sengos, Paul DePietro, Charles M. LeVea, Amy Early, Hongbin Chen, Anne Grand’Maison, Patrick Boland, Marc S. Ernstoff, Stephen Edge, Stacey Akers, Mateusz Opyrchal, Gurkamal Chatta, Kunle Odunsi, Sarabjot Pabla, Jeffrey M. Conroy, Sean T. Glenn, Hanchun T. DeFedericis, Blake Burgher, Jonathan Andreas, Vincent Giamo, Maochun Qin, Yirong Wang, Kazunori Kanehira, Felicia L. Lenzo, Peter Frederick, Shashikant Lele, Lorenzo Galluzzi, Boris Kuvshinoff, Carl Morrison
Format: Article
Language:English
Published: BMC 2019-01-01
Series:BMC Medical Informatics and Decision Making
Subjects:
Next generation sequencing
Comprehensive genomic profiling
FDA guidance
Physician treatment recommendations
Online Access:http://link.springer.com/article/10.1186/s12911-019-0743-x

Internet

http://link.springer.com/article/10.1186/s12911-019-0743-x

Similar Items